[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-405741-105":59,"doc-detail-405741-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","treatment-of-g1-duodenal-neuroendocrine-tumors-with-hepatic-metastasis-a-case-report","Treatment of G1 Duodenal Neuroendocrine Tumors With Hepatic Metastasis - A Case Report","","HAIC-FOLFOX combined with lenvatinib induced complete response of liver metastases and partial response of the primary G1 duodenal neuroendocrine tumor, allowing curative resection with 13 months recurrence-free survival. The case involved a 66-year-old woman with duodenal papilla disease, confirmed by imaging and immunohistochemistry and staged using WHO 2022 criteria. The report highlights a conversion strategy for advanced dNETs presenting with hepatic metastasis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/treatment-of-g1-duodenal-neuroendocrine-tumors-with-hepatic-metastasis-a-case-report/405741/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/treatment-of-g1-duodenal-neuroendocrine-tumors-with-hepatic-metastasis-a-case-report/405741.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment combination was used to manage hepatic metastasis in this G1 duodenal neuroendocrine tumor case?","Question",{"text":112,"@type":113},"The patient received conversion therapy with hepatic artery infusion chemotherapy using mFOLFOX (HAIC-mFOLFOX) combined with lenvatinib to downstage the disease and enable radical surgery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the duodenal neuroendocrine tumor diagnosis confirmed?",{"text":117,"@type":113},"Diagnosis was supported by imaging findings of a duodenal papilla mass and pathological confirmation through immunohistochemistry, including the reported Ki-67 proliferation index of about 2%.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment outcome was reported after conversion therapy and surgery?",{"text":121,"@type":113},"Complete response was achieved for liver metastases and partial response for the primary tumor, leading to curative resection and 13 months recurrence-free survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},405741,1790698511,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Clinical Case Reports  \nCASE REPORT  OPEN ACCESS   \nTreatment of G1 Duodenal Neuroendocrine Tumors With Hepatic Metastasis: A Case Report  \nYuhui Fang1  | Yuquan Chang2 | Yilin Qiu2 | Ruiqin Huang1 | Feng Tian2 | Qijie Luo1 | Dongdong Huang1 | Kun He1  1Department of Hepatobiliary Surgery, Zhongshan City People's Hospital, Zhongshan, China | 2Guangdong Medical University, Zhanjiang, China Correspondence: Kun He ([hekun80@126.com](hekun80@126.com))  \nReceived: 8 May 2025 | Revised: 14 November 2025 | Accepted: 21 December 2025  \nKeywords: case report | duodenal neuroendocrine tumors | HAIC | liver metastases  \n\n| ABSTRACT\u003Cbr>HAIC-FOLFOX combined with lenvatinib induced complete liver metastasis response and partial primary tumor response in G1 duodenal neuroendocrine tumor, enabling curative resection (13 months recurrence free survival), highlighting a novel conversion strategy for advanced dNETs with liver metastases. |  |\n| --- | --- |\n| 1 | Background | admission was unremarkable, except for tenderness in the upper abdomen. Laboratory tests revealed liver dysfunction, with ALT |\n| Neuroendocrine tumors (NETs) are rare neoplasms originating | at 98 U/L, AST at 56 U/L, ALP at 141 U/L, and Alb at 39 g/L. |\n| from neuroendocrine cells, and their prevalence has increased | Routine blood tests, biochemical analyses, and tumor marker |\n| in recent years. The overall incidence of duodenal neuroendocrine tumors (dNETs) remains relatively low, accounting for only 2.8% of all NETs and 2%–3% of gastrointestinal NETs [1, 2] . | assessments showed no significant abnormalities. |\n| However, dNETs are highly invasive and carry a significant risk of distant metastasis. Studies have shown that 10%–15% of | 2.2 | Imaging and Pathological Findings |\n| patients with dNETs present with liver metastases [3, 4] . In line | Both magnetic resonance cholangiopancreatography (MRCP) |\n| with existing literature, we report a case of dNET with liver | and contrast-enhanced abdominal computed tomography (CT) |\n| metastasis in a 66-year-old woman. We hope this report will | revealed a lobulated mass at the major duodenal papilla, mea- |\n| improve the understanding of the diagnosis and treatment of | suring approximately 25 × 18 mm in diameter, which was sus- |\n| this disease. | pected to be a malignant tumor (Figure 1). After discussion with the patient, an esophagogastroduodenoscopy (EGD) with biopsy was performed. The EGD revealed a prominent mass at the du- |\n| 2 | Case Report | odenal papilla (Figure 2), and tissue samples were obtained for pathological examination. Immunohistochemistry (IHC) con- |\n| 2.1 | Patient Information | firmed the diagnosis of a dNET (Figure 3) . Histologically, hematoxylin and eosin (H&E) staining revealed no heterogeneity |\n| The patient was a 66-year-old woman presenting with recur- | in the mucosal layer, with cells arranged in nests, fuzzy tissue |\n| rent right upper abdominal pain that had persisted for 1 week. | architecture, and focally hyperchromatic nuclei. The immuno- |\n| Previous examinations at a local hospital suggested “choledo- | profile revealed the following: chromogranin A (CgA–), CD56–, |\n| cholithiasis”. However, her symptoms continued despite analge- | synaptophysin (Syn+), cytokeratin (CK+), and a Ki-67 prolifera- |\n| sic and anti-inflammatory therapy. Physical examination upon | tion index of approximately 2% . To assess the tumor staging, we |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.\u003Cbr>© 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. |  |\n\nClinical Case Reports, 2026; 14:e71764 1 of 7  \n[https://doi.org/10.1002/ccr3.71764](https://doi.org/10.1002/ccr3.71764)  \nFIGURE 1 | Patient's imaging findings. (A) Noncontrast CT scan showing d","cbCairxU1fsrTulN","https://ap.wps.com/l/cbCairxU1fsrTulN","pdf",1489674,"English","# Background\n# Case Report\n## Patient Information\n## Imaging and Pathological Findings\n## Treatment\n# Discussion","[{\"question\":\"What treatment combination was used to manage hepatic metastasis in this G1 duodenal neuroendocrine tumor case?\",\"answer\":\"The patient received conversion therapy with hepatic artery infusion chemotherapy using mFOLFOX (HAIC-mFOLFOX) combined with lenvatinib to downstage the disease and enable radical surgery.\"},{\"question\":\"How was the duodenal neuroendocrine tumor diagnosis confirmed?\",\"answer\":\"Diagnosis was supported by imaging findings of a duodenal papilla mass and pathological confirmation through immunohistochemistry, including the reported Ki-67 proliferation index of about 2%.\"},{\"question\":\"What treatment outcome was reported after conversion therapy and surgery?\",\"answer\":\"Complete response was achieved for liver metastases and partial response for the primary tumor, leading to curative resection and 13 months recurrence-free survival.\"}]","Treatment of G1 Duodenal Neuroendocrine Tumors With Hepatic Metastasis - A Case Report | PDF",1790561651,18]